Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Employees - 130, CEO - Leon Oliver Moulder Jr.,, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 4.34, Piotroski Score(max is 10): 2, Working Capital: $225359000, Total Assets: $293085000, Retained Earnings: $-473187000, EBIT: -185560000, Total Liabilities: $53459000, Revenue: $15000000

AryaFin Target Price - $7.55 - Current Price $ - Analyst Target Price $